Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan

International Journal of Hematology

Volumn 91, Issue 3, 2010, Pages 446-455

  Itoh, Kuniaki ^a   Kinoshita, Tomohiro ^b   Watanabe, Takashi ^c   Yoshimura, Kenichi ^d   Okamoto, Rumiko ^e   Chou, Takaaki ^f   Ogura, Michinori ^g   Hirano, Masami ^h   Asaoku, Hideki ⁱ   Kurosawa, Mitsutoshi ^j   Maeda, Yoshiharu ^e   Omachi, Ken ^k   Moriuchi, Yukiyoshi ^l   Kasai, Masaharu ^m   Ohnishi, Kazunori ⁿ   Takayama, Nobuyuki ^o   Morishima, Yasuo ^g   Tobinai, Kensei ^c   Kaba, Harumi ^d   Yamamoto, Seiichiro ^d   Fukuda, Haruhiko ^d   Kikuchi, Masahiro ^p   Yoshino, Tadashi ^q   Matsuno, Yoshihiro ^r   Hotta, Tomomitsu ^s   Shimoyama, Masanori ^c   more..

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f NIIGATA CANCER CENTER HOSPITAL   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^j HOKKAIDO CANCER CENTER   (Japan)

^k TOKAI UNIVERSITY   (Japan)

^l Sasebo Shiritsu Sogo Hospital   (Japan)

^m SAPPORO HOKUYU HOSPITAL   (Japan)

ⁿ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o KYORIN UNIVERSITY   (Japan)

^p FUKUOKA UNIVERSITY   (Japan)

^q OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^r HOKKAIDO UNIVERSITY   (Japan)

^s NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

International prognostic score; LDH; Male gender; Multicenter phase II trial; Overall survival; Prognostic factor

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER STAGING; CLINICAL TRIAL; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JAPAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; SEX DIFFERENCE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOTHERAPY; REMISSION INDUCTION; RISK FACTORS; YOUNG ADULT;

EID: 77950916831     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0533-9     Document Type: Article

References (33)

1. AM Evens M Hutchings V Diehl 2008 Treatment of Hodgkin lymphoma: the past, present, and future Nat Clin Pract Oncol 5 543 556 10.1038/ncponc1186 1:CAS:528:DC%2BD1cXhtVGgt7fP 18679394
2. J Franklin A Pluetschow M Paus L Specht AP Anselmo A Aviles, et al. 2006 Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann Oncol 17 1749 1760 10.1093/annonc/mdl302 1:STN:280:DC%2BD28jhtlWhuw%3D%3D 16984979 (Pubitemid 44884048)
3. SJ Schonfeld ES Gilbert GM Dores CF Lynch DC Hodgson P Hall, et al. 2006 Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35 511 patients J Natl Cancer Inst 98 215 218 16449681 (Pubitemid 43205483)
4. DC Hodgson 2008 Hodgkin lymphoma: the follow-up of long-term survivors Hematol Oncol Clin N Am 22 233 244 10.1016/j.hoc.2008.01.004 (Pubitemid 351452097)
5. ML De Bruin LDA Dorresteijn MB van't Veer ADG Krol HJ van der Pal AC Kappelle, et al. 2009 Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma J Natl Cancer Inst 101 928 937 10.1093/jnci/djp147 19535773
6. T Zander S Wiedemann J Wolf 2002 Prognostic factors in Hodgkin's lymphoma Ann Oncol 13 Supple 1 67 74 12078906 (Pubitemid 34567404)
7. D Hasenclever V Diehl for the international prognostic factors project on advanced Hodgkin's disease 1998 A prognostic score for advanced Hodgkin's disease N Engl J Med 339 1506 1514 10.1056/NEJM199811193392104 1:STN:280:DyaK1M%2FisFenuw%3D%3D 9819449 (Pubitemid 28543499)
8. Ogura M, Kagami Y, Itoh K, Sasaki Y, Kinoshita T, Tobinai K, et al. Phase II study of ABVD therapy to advanced stage Hodgkin's disease in Japan: JCOG study 9305. Proc Am Soc Clin Oncol. 2001;230a.
9. Ogura M, Morishima Y, Itoh K, Tobinai K, Kinoshita T, Okamoto M, et al. Dacarbazine (DTIC) cannot be deleted from ABVD therapy for advanced Hodgkin lymphoma (HL): Japan Clinical Oncology Group (JCOG) Study 9705. Proc Am Soc Clin Oncol. 2003;573a.
10. T Kinoshita T Hotta K Tobinai T Kobayashi N Ishizuka M Tomonaga, et al. 2004 Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG): A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002 Int J Hematol 80 341 350 10.1532/IJH97.04085 1:CAS:528:DC%2BD2cXhtFakurrO 15615259 (Pubitemid 39564635)
11. SJ Proctor J Wilkinson M Sieniawski 2009 Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future Crit Rev Oncol/Hematol 71 222 232 10.1016/j.critrevonc.2008.12.007 1:STN:280: DC%2BD1MrisFeqtg%3D%3D
12. C Allemani M Sant R De Angelis R Marcos-Gragera JW Coebergh the EUROCARE Working Group 2006 Hodgkin disease survival in Europe and the US prognostic significance of morphologic groups Cancer 107 352 360 10.1002/cncr.21995 16770772 (Pubitemid 44036565)
13. DG Altman P Royston 2000 What do we mean by validating a prognostic model? Statist Med 19 453 473 10.1002/(SICI)1097-0258(20000229)19:4<453::AID- SIM350>3.0.CO;2-5 1:STN:280:DC%2BD3c7mtV2ltQ%3D%3D (Pubitemid 30126878)
14. P Royston KGM Moons DG Altman Y Vergouwe 2009 Prognosis and prognostic research: developing a prognostic model BMJ 338 1373 1377 10.1136/bmj.b604
15. Lymphoma Study Group of Japanese Pathologists 2000 The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities Pathol Int 50 696 702 10.1046/j.1440-1827.2000. 01108.x
16. J Hochberg IM Waxman KM Kelly E Morris MS Cairo 2009 Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science Brit J Haematol 144 24 40 10.1111/j.1365-2141.2008.07393.x
17. N Asano A Oshiro K Matsuo Y Kagami F Ishida R Suzuki, et al. 2006 Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study J Clin Oncol 24 4626 4633 10.1200/JCO.2006.06.5342 16954517 (Pubitemid 46630961)
18. TP Vassilakopoulos MK Angelopoulou MP Siakantaris FN Kontopidou MN Dimopoulou A Barbounis, et al. 2001 Prognostic factors in advanced stage Hodgkin's lymphoma; the significance of the number of involved anatomic sites Euro J Hematol 67 279 288 10.1034/j.1600-0609.2001.00561.x 1:STN:280: DC%2BD387js1Cktw%3D%3D (Pubitemid 34135440)
19. U Axdorph J Sjoberg G Grimfors O Landgren A Porwit-MacDonald M Bjorkholm 2000 Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease Ann Oncol 11 1405 1411 10.1023/A:1026551727795 1:STN:280:DC%2BD3M7lt12rtA%3D%3D 11142480
20. B Klimm T Reineke H Haverkamp K Behringer HT Eich A Josting, et al. 2005 Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin study group J Clin Oncol 23 8003 8011 10.1200/JCO.2005.205.60 1:CAS:528:DC%2BD2MXht1CqsL%2FP 16204002 (Pubitemid 46657401)
21. NA Dobbs CJ Twelvws H Gillies CA James PG Harper RD Rubens 1995 Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry Cancer Chemother Pharmacol 36 473 476 10.1007/BF00685796 1:CAS:528: DyaK2MXptlGmtL8%3D 7554038
22. DJ Straus JJ Gaynor J Myers DP Merke J Caravelli D Chapman, et al. 1990 Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy J Clin Oncol 8 1173 1186 1:STN:280:DyaK3c3ptlyjtg%3D%3D 1694235 (Pubitemid 20195627)
23. R García JM Hernández MD Caballero M González J Galende MC del Cañizo, et al. 1993 Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease Br J Cancer 68 1227 1231 8260377 (Pubitemid 23356681)
24. The international non-Hodgkin's lymphoma prognostic factors project 1993 A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 987 994 10.1056/NEJM199309303291402 (Pubitemid 23307906)
25. S Derkson HJ Keselman 1992 Backward, forward and stepwise automated subset selection algorithms: frequency of obtaining authentic and noise variables Br J Math Stat Psychol 45 265 282
26. PC Austina JV Tu 2004 Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality J Clin Epidemiol 57 1138 1146 10.1016/j.jclinepi.2004.04.003 (Pubitemid 39573020)
27. VF Flack PC Chang 1987 Frequency of selecting noise variables in subset regression analysis: a simulation study Am Stat 14 84 86 10.2307/2684336
28. JB Copas T Long 1991 Estimating the residual variance in orthogonal regression with variable selection Statistician 40 51 59 10.2307/2348223
29. P Litam S Swan F Cabanillas SL Tucker P McLaughlin FB Hagemeister, et al. 1991 Prognostic value of serum β2 microglobulin in low-grade lymphoma Ann Intern Med 114 855 860 1:STN:280:DyaK3M7ps12qsA%3D%3D 2014946
30. F Swan WS Velasquez S Tucker JR Redman MA Rodriguez P McLaughlin, et al. 1989 A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels J Clin Oncol 7 1518 1527 2674337 (Pubitemid 19245124)
31. MA Dimopoulos F Cabanillas JJ Lee F Swan L Fuller PK Allen, et al. 1993 Prognostic role of serum β2 microglobulin in Hodgkin's disease J Clin Oncol 11 1108 1111 1:STN:280:DyaK3s3nsVegtA%3D%3D 8501496 (Pubitemid 23163351)
32. GM Chronowski RB Wilder SL Tucker CS Ha AH Sarris FB Hagemeister, et al. 2002 An elevated serum β-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease Cancer 95 2534 2538 10.1002/cncr.10998 1:CAS:528:DC%2BD38Xpslehsbg%3D 12467067 (Pubitemid 35424039)
33. TP Vassilakopoulos G Nadali MK Angelopoulou MP Siakantaris MN Dimopoulou FN Kontopidou, et al. 2002 The prognostic significance of β2-microglobulin in patients with Hodgkin's lymphoma Haematologica 87 701 708 1:CAS:528:DC%2BD38XmsVKkt7s%3D 12091120 (Pubitemid 34787140)